Market closedADR

Evotec/$EVO

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Evotec

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Ticker

$EVO

Sector

Health Care

Trading on

NASDAQ

Industry

Life Sciences Tools & Services

Headquarters

Hamburg, Germany

Employees

5,007

Website

www.evotec.com

Evotec Metrics

BasicAdvanced

$1.5B

-

-$0.99

0.98 -

Price and volume

Market cap

$1.5B

Beta

0.98

52-week high

$8.39

52-week low

$2.85

Average daily volume

168K

Financial strength

Current ratio

2.093

Quick ratio

1.592

Long term debt to equity

43.007

Total debt to equity

48.535

Interest coverage (TTM)

-5.75%

Management effectiveness

Return on assets (TTM)

-1.77%

Return on equity (TTM)

-16.25%

Valuation

Price to revenue (TTM)

0.93

Price to book

1.48

Price to tangible book (TTM)

2.12

Price to free cash flow (TTM)

-3.454

Growth

Revenue change (TTM)

-5.33%

Earnings per share change (TTM)

80.05%

3-year revenue growth (CAGR)

10.79%

3-year earnings per share growth (CAGR)

-13.53%

What the Analysts think about Evotec

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Evotec stock.

Evotec Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

Evotec Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Evotec News

AllArticlesVideos

Evotec SE announces first projects for LAB eN(2) drug discovery accelerator with Novo Nordisk

Accesswire·1 month ago

Evotec Announces Change in Management Board

Accesswire·2 months ago

Comment on Withdrawn Non-Binding Offer

Accesswire·2 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $EVO

$

Capital at risk

Market closedADR

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Evotec stock?

Evotec (EVO) has a market cap of $1.5B as of January 15, 2025.

What is the P/E ratio for Evotec stock?

The price to earnings (P/E) ratio for Evotec (EVO) stock is 0 as of January 15, 2025.

Does Evotec stock pay dividends?

No, Evotec (EVO) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Evotec dividend payment date?

Evotec (EVO) stock does not pay dividends to its shareholders.

What is the beta indicator for Evotec?

Evotec (EVO) has a beta rating of 0.98. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.